CUMYL-3TMS-PRINACA

From WikiProjectMed
Jump to navigation Jump to search
CUMYL-3TMS-PRINACA
Identifiers
  • N-(2-phenylpropan-2-yl)-1-(3-(trimethylsilyl)propyl)-1H-indazole-3-carboxamide
Chemical and physical data
FormulaC23H31N3OSi
Molar mass393.606 g·mol−1
3D model (JSmol)
  • C[Si](C)(C)CCCn1nc(C(=O)NC(C)(C)c2ccccc2)c2ccccc12

CUMYL-3TMS-PRINACA is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first identified in Sweden in May 2023. Along with the related compound ADMB-3TMS-PRINACA that was reported several months earlier, CUMYL-3TMS-PRINACA is one of the only psychoactive drugs ever reported that contains a silicon atom.[1]

Legality

CUMYL-3TMS-PRINACA is illegal in Germany and Italy and has been recommended for control in Sweden.[2][3]

See also

References

  1. ^ "New psychoactive substances - the current situation in Europe" (PDF). European Drug Report. European Union Drugs Agency (EUDA). 2024.
  2. ^ [1]
  3. ^ [2]


Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/CUMYL-3TMS-PRINACA"